Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

• Published in: Reviews in medical virology 2023-05, Vol.33 (3), p.e2332-n/a
• Main Authors: Jordan, Karen, Murchu, Eamon O., Comber, Laura, Hawkshaw, Sarah, Marshall, Liam, O’Neill, Michelle, Teljeur, Conor, Harrington, Patricia, Carnahan, Annasara, Pérez‐Martín, Jaime Jesús, Robertson, Anna Hayman, Johansen, Kari, Jonge, Jorgen de, Krause, Tyra, Nicolay, Nathalie, Nohynek, Hanna, Pavlopoulou, Ioanna, Pebody, Richard, Penttinen, Pasi, Soler‐Soneira, Marta, Wichmann, Ole, Ryan, Máirín
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; cell‐based; Hospitalization; Humans; Immunization; Influenza; Influenza A; Influenza B; Influenza Vaccines; Influenza, Human; Optaflu; Placebos; Safety; Seasons; systematic review; Vaccination; vaccine effectiveness; Vaccine efficacy; Vaccines
• ISSN: 1052-9276; 1099-1654
• DOI: 10.1002/rmv.2332

The most effective means of preventing seasonal influenza is through strain‐specific vaccination. In this study, we investigated the efficacy, effectiveness and safety of cell‐based trivalent and quadrivalent influenza vaccines. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) were eligible for inclusion. Two reviewers independently screened, extracted data and assessed the risk of bias of included studies. Certainty of evidence for key outcomes was assessed using the GRADE methodology. The search returned 28,846 records, of which 868 full‐text articles were assessed for relevance. Of these, 19 studies met the inclusion criteria. No relative efficacy data were identified for the direct comparison of cell‐based vaccines compared with traditional vaccines (egg‐based). Efficacy data were available comparing cell‐based trivalent influenza vaccines with placebo in adults (aged 18–49 years). Overall vaccine efficacy was 70% against any influenza subtype (95% CI 61%–77%, two RCTS), 82% against influenza A(H1N1) (95% CI 71%–89%, 2 RCTs), 72% against influenza A(H3N2) (95% CI 39%–87%, 2 RCTs) and 52% against influenza B (95% CI 30%–68%, 2 RCTs). Limited and heterogeneous data were presented for effectiveness when compared with no vaccination. One NRSI compared cell‐based trivalent and quadrivalent vaccination with traditional trivalent and quadrivalent vaccination, finding a small but significant difference in favour of cell‐based vaccines for influenza‐related hospitalisation, hospital encounters and physician office visits. The safety profile of cell‐based trivalent vaccines was comparable to traditional trivalent influenza vaccines. Compared with placebo, cell‐based trivalent influenza vaccines have demonstrated greater efficacy in adults aged 18–49 years. Overall cell‐based vaccines are well‐tolerated in adults, however, evidence regarding the effectiveness of these vaccines compared with traditional seasonal influenza vaccines is limited.